In $86M IPO pitch, Mirum spells out plans to turn Shire discards into orphan liver drug successes

Mike Grey doesn’t have any time to waste. Having regained control of two liver disease drugs from Shire and positioned them for pivotal studies — five years after first handing them off in a deal to sell Lumena, where he was CEO — Grey is steering Mirum straight into an IPO with a $86 million ask.